Literature DB >> 3135553

Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen.

E J Pearce1, S L James, S Hieny, D E Lanar, A Sher.   

Abstract

Paramyosin (Sm97), a 97-kDa myofibrillar protein identified by the unusually monospecific antibody response induced by intradermal vaccination of mice with a complex soluble worm antigen preparation (SWAP) of adult Schistosoma mansoni administered with bacillus Calmette-Guérin (BCG), was purified and tested for its capacity to protect mice against challenge infection. When administered intradermally with BCG at total doses of only 4-40 micrograms per mouse, both the native molecule and a recombinant expression product containing approximately 50% of the whole protein were found to confer significant resistance (26-33%) against challenge infection, while 2 mg of unfractionated SWAP was required to induce similar levels of protection. In addition, paramyosin was shown to stimulate T lymphocytes from vaccinated mice to produce lymphokines [e.g., gamma interferon (IFN-gamma)] that activate macrophages to kill schistosomula. Neither schistosome myosin nor a heterologous paramyosin from a different invertebrate genus were protective, indicating a requirement for specific epitopes in the immunization. That the protection induced by paramyosin involves a T-cell-mediated mechanism was supported by the failure of anti-paramyosin antibodies to passively transfer significant resistance to infection to recipient mice. Lymphocytes from mice vaccinated with paramyosin were found to produce IFN-gamma in response to living schistosomula, suggesting that during challenge infection of vaccinated hosts, paramyosin (a nonsurface antigen) may elicit a protective T-cell response as a consequence of its release from migrating parasite larvae. Paramyosin-depleted SWAP was also found to be protective as well as stimulatory for T lymphocytes from SWAP-vaccinated mice, indicating that other antigens in this preparation may have immunoprophylactic potential. In summary, these results (i) suggest that the induction of T-cell-dependent cell-mediated immunity against soluble nonsurface antigens may be an effective strategy for immunization against multicellular parasites and (ii) in the case of schistosomes, identify paramyosin as a candidate vaccine immunogen in this category.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135553      PMCID: PMC281823          DOI: 10.1073/pnas.85.15.5678

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Myosin and paramyosin of Caenorhabditis elegans: biochemical and structural properties of wild-type and mutant proteins.

Authors:  H E Harris; H F Epstein
Journal:  Cell       Date:  1977-04       Impact factor: 41.582

2.  Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine is dependent on the method of antigen presentation.

Authors:  S L James
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

3.  Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. II. Response of mouse strains with selective immune defects.

Authors:  S L James; L A DeBlois
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

4.  Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. III. Correlation of resistance with induction of activated larvacidal macrophages.

Authors:  S L James
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

5.  Ultrastructural studies of the killing of schistosomula of Schistosoma mansoni by activated macrophages in vitro.

Authors:  D J McLaren; S L James
Journal:  Parasite Immunol       Date:  1985-05       Impact factor: 2.280

6.  Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll.

Authors:  J K Lazdins; M J Stein; J R David; A Sher
Journal:  Exp Parasitol       Date:  1982-02       Impact factor: 2.011

7.  Comparison of Schistosoma mansoni migration patterns in normal and irradiated cercaria-immunized mice by means of autoradiographic analysis. Evidence that worm elimination occurs after the skin phase in immunized mice.

Authors:  D A Dean; B L Mangold; J R Georgi; R H Jacobson
Journal:  Am J Trop Med Hyg       Date:  1984-01       Impact factor: 2.345

8.  Defective vaccine-induced immunity to Schistosoma mansoni in P strain mice. II. Analysis of cellular responses.

Authors:  S L James; R Correa-Oliveira; E J Leonard
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

9.  Induction of protective immunity against Schistosoma mansoni by a non living vaccine. I. Partial characterization of antigens recognized by antibodies from mice immunized with soluble schistosome extracts.

Authors:  S L James; E J Pearce; A Sher
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

10.  The glutathione transferase activity and tissue distribution of a cloned Mr28K protective antigen of Schistosoma mansoni.

Authors:  J B Taylor; A Vidal; G Torpier; D J Meyer; C Roitsch; J M Balloul; C Southan; P Sondermeyer; S Pemble; J P Lecocq
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

View more
  38 in total

1.  Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.

Authors:  T Ben-Yedidia; R Tarrab-Hazdai; D Schechtman; R Arnon
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

3.  Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.

Authors:  R D Bungiro; M Goldberg; P K Suri; P M Knopf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Screening the Schistosoma mansoni transcriptome for genes differentially expressed in the schistosomulum stage in search for vaccine candidates.

Authors:  Leonardo P Farias; Cibele A Tararam; Patricia A Miyasato; Milton Y Nishiyama; Katia C Oliveira; Toshie Kawano; Sergio Verjovski-Almeida; Luciana Cezar de Cerqueira Leite
Journal:  Parasitol Res       Date:  2010-09-18       Impact factor: 2.289

5.  Paramyosin of Echinococcus granulosus: cDNA sequence and characterization of a tegumental antigen.

Authors:  F Mühlschlegel; L Sygulla; P Frosch; P Massetti; M Frosch
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

6.  Pure paraflagellar rod protein protects mice against Trypanosoma cruzi infection.

Authors:  R A Wrightsman; M J Miller; J L Saborio; J E Manning
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Excretory/secretory proteome of the adult developmental stage of human blood fluke, Schistosoma japonicum.

Authors:  Feng Liu; Shu-Jian Cui; Wei Hu; Zheng Feng; Zhi-Qin Wang; Ze-Guang Han
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

8.  cDNA cloning and functional expression of the Schistosoma mansoni protective antigen triose-phosphate isomerase.

Authors:  C Shoemaker; A Gross; A Gebremichael; D Harn
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Molecular cloning and characterization of a paramyosin from Clonorchis sinensis.

Authors:  Tae-Joon Park; Jung-Mi Kang; Byoung-Kuk Na; Woon-Mok Sohn
Journal:  Korean J Parasitol       Date:  2009-12-01       Impact factor: 1.341

Review 10.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.